Search Weight Loss Topics:




Nov 30

BioCorRx on growth fast-track with robust pipeline, programs for substance use recovery, weight loss – Proactive Investors USA & Canada

Long Term Weight Loss Comments Off on BioCorRx on growth fast-track with robust pipeline, programs for substance use recovery, weight loss – Proactive Investors USA & Canada

BioCorRX Inc () is a healthcare company that's focused on developing advanced treatment solutions for addiction, weight loss, and other related disorders.

The company is led by industry veteran Brady Granier, who was born in the heart of Cajun Country in southeast Louisiana where he started working at the age of 11 to support his single mother and younger brother.

It's personal for Granier, who has family members with addiction in their past. He has also worked as a nurse in the emergency room at White Memorial Hospital in Los Angeles. Granier, who has gone onto spearheading marketing campaigns for national brands, has sharpened BioCorRxs focus on providing alcohol and opioid addiction treatment programs to rehab centers in the US.

Through its subsidiaries, the Anaheim, California-based company licenses the BioCorRx Recovery Program, a non-addictive, medication-assisted treatment (MAT) program for substance use to healthcare providers and clinics.

The first component of the BioCorRx Recovery Program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers naltrexone which reduces cravings for alcohol and opioids. Secondly, the program relies on cognitive behavioral therapy modules and peer support built around long-term use of sustained-release naltrexone.

Similarly, the UnCraveRx Weight Loss Program is also a medication-assisted program that helps to reduce food cravings combined with on-demand virtual lifestyle support, fitness and nutrition.

The company conducts R&D under its subsidiary BioCorRx Pharmaceuticals. It is developing BICX101, an extended-release injectable formulation of naltrexone. BioCorRx is also working to create an implant, named BICX102 that will help people kick their addiction to both opioids and alcohol.

The BICX102 implant uses naltrexone, a drug already approved by the FDA, as an every-day pill or a once-per-month shot. Naltrexone blocks receptors in the brain so that opioids or alcohol won't impact people who use them. The company is creating an implant that lasts three months which will make it more likely that people will be able to beat their addiction. BICX102 will be surgically implanted ina person's adiposetissue, orstomach fat, and dissolve slowly over three months.

Experts say America is in the throes of an opioid epidemic. Nearly 23.5 million Americans are addicted to drugs, alcohol and misuse opioids, according to the Substance Abuse and Mental Health Services Administration.

As a result, the over $40 billion addiction treatment market is seeking radical transformation in the shape of effective new treatments. BioCorRX is leading the change by offering a two-pronged approach to the treatment of substance abuse addiction.

Medication-assisted treatment (MAT) the use of medication combined with counselling and behavioural therapies which is the BioCorRX way, is one of the major pillars of the federal response to the opioid epidemic in America.

In a positive sign, BioCorRx recentltyreceived a $5.7 million grant from the National Institute on Drug Abuse (NIDA) for the development of BICX102. It will last two years, which the company says will fund the research through the development of the implant and some early testing.

The grant validates the clinical potential of BICX102 which has several advantages over current buprenorphine implants as it fully biodegrades, eliminating the need to remove and replace the implant. It also maintains therapeutic plasma levels for up to three months, said the company, while future versions are expected to last longer. The companys goal is to give a person a longer time period to address addiction issues without the intrusive cravings kicking in.

BioCorRx is seeking a more rapid and cost-effective 505(b)(2) regulatory pathway for its naltrexone implant. Towards that end, it has partnered with IRISYS to manufacture and develop BICX102.

The company has a master services agreement with Charles River Laboratories which is conducting preclinical studies of BICX102. If things go according to plan, the company aims to start human studies next year.

On a separate note, BioCorRx is also developing BICX101, an extended-release injectable formulation of naltrexone. It acquired Therakine patented micro-delivery technology for development of a new injectable version of naltrexone. Currently the product is in the formulation development and preclinical phase.

In April, the company raised $6 million at a premium to its market price from two investors.

The company has also been backed by Alpine Creek Capital which first invested $2.5 million when BioCorRx had a market cap of just $3 million. Alpine Creek Capital followed up their initial investment with an additional tranche in the first quarter of 2017.

BioCorRx said a senior secured convertible promissory note of $4.16 million with BICX Holding, an entity controlled by Alpine Creek Capital, was recently converted into 2.22 million shares of common stock in order to simplify the company's capital structure and boost its balance sheet.

Significantly, the timely conversion eliminated $4.16 million of liabilities from the companys balance sheet.

BioCorRXs goal is to get Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to go into human trials of BICX102, it's lead pipeline candidate. The company is hoping this will come to fruition in the second half of 2020.

The companys new medically-assisted UnCraveRx Weight Loss Program is likely to be a key growth revenue driver as it looks to expand its provider network.

UnCraveRx, which launched in October, is a 12-week program that combines a sustained-release anti-craving medication with an app that provides access to on-demand virtual fitness, nutrition and behavior lifestyle group support.

The company is likely to get strong traction from its new UnCraveRx Weight Loss Program, coupled with the private placement funding and the $5.7 million NIDA grant for BICX102. All these drivers should help the promising healthcare company accelerate its product development and growth strategy.

Its no secret that BioCorRx is eying a Nasdaq listing and has enhanced its capital structure and improved its balance sheet to prepare for the planned up-listing to the tech-laden exchange. The move will give the company access to a wider investor base.

In an interview withProactive,BioCorRX IncCEO Brady Granier said: We have a clean balance sheet, no toxic loans, strong management, independent board, strategic investors, products/programs that do work, government funding for R&D. We operate lean and are poised for growth.

He added: We feel undervalued based on the accomplishments of this year alone with raising funds at a premium to market plus the NIDA grant award. We raised about $6-$7 million in the last year alone at a premium.

Contact Uttara Choudhury at[emailprotected]

Follow her onTwitter:@UttaraProactive

See the original post here:
BioCorRx on growth fast-track with robust pipeline, programs for substance use recovery, weight loss - Proactive Investors USA & Canada

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker